Archives
-
AmpC/AmpD Resistance to Ceftolozane-Tazobactam
2026-09-29
Deroche et al. combined targeted mutant construction, sequential time-kill experiments, and semi-mechanistic PKPD modeling to quantify how AmpC G183D and AmpD H157Y mutations drive treatment-emergent ceftolozane-tazobactam resistance in Pseudomonas aeruginosa. The study distinguishes baseline susceptibility shifts from time-dependent adaptive resistance, showing why MIC measurements alone can miss important resistance dynamics.
-
AZD3463: A Translational Framework for ALK Research
2026-09-28
AZD3463 is a dual ALK/IGF1R inhibitor that links pathway biology with practical neuroblastoma assay design. This thought-leadership guide examines mechanistic validation, reproducibility, combination studies, translational boundaries, and how evidence from chemically defined iPSC differentiation can sharpen ALK-driven cancer research.
-
Ertapenem in CREC Resistance Workflows
2026-09-28
Use Ertapenem sodium salt as a controlled phenotypic probe alongside gene detection—not as a substitute for carbapenemase testing—in Enterobacter cloacae resistance studies. This workflow connects broth microdilution with plasmid-transfer and genotype analysis to help distinguish changes in susceptibility from the spread of resistance determinants.
-
Ceftazidime as a Lens on Resistance Phenotypes
2026-09-27
Ceftazidime, a third-generation cephalosporin with notable activity against Pseudomonas aeruginosa, can help frame careful Gram-negative susceptibility research. This article connects its assay role to recent carbapenem-resistant Enterobacter cloacae findings while clarifying what those results do—and do not—show about ceftazidime.
-
Temafloxacin: Reading MICs for Better Assay Design
2026-09-26
Temafloxacin is a fluoroquinolone broad-spectrum antibacterial agent whose activity is best interpreted through pathogen-specific MICs and assay conditions. This guide connects historical comparative data with practical choices for respiratory, atypical, and intracellular antibacterial research.
-
Aztreonam Workflows for Gram-Negative Research
2026-09-25
Use Aztreonam as a mechanism-focused comparator in Gram-negative bacterial assays, with practical guidance for solution preparation, susceptibility workflows, and troubleshooting. The article also separates its microbiology applications from the distinct progenitor-cell and hepatic enzyme findings that can inform preclinical research.
-
Aztreonam: Mechanism to Translational Strategy
2026-09-25
Aztreonam offers translational researchers a focused tool for studying Gram-negative bacterial cell-wall biology, resistance, and selected host-side effects. This article connects its monocyclic β-lactam mechanism to assay design, resistance-era interpretation, and the limits of extrapolating preclinical findings.
-
Evacetrapib (LY2484595): Assay Context and Limits
2026-09-24
Evacetrapib (LY2484595) is a CETP inhibitor, while recent NSCLC research identifies a distinct H₂S–SAHH pathway that can sensitize cells to ferroptosis. This article clarifies what the findings do—and do not—justify when planning experiments across these research areas.
-
Ceftolozane/Tazobactam: Mechanism and Evidence
2026-09-24
This 2015 review synthesizes the pharmacology and clinical evidence for ceftolozane/tazobactam, emphasizing ceftolozane’s activity against Pseudomonas aeruginosa and the added ESBL coverage provided by tazobactam. Its practical contribution is a framework for interpreting spectrum, pharmacokinetic/pharmacodynamic targets, dosing considerations, and the evidence available for complicated urinary and intra-abdominal infections.
-
Tigecycline: Mechanism, Evidence, and Research Use
2026-09-23
Tigecycline is a glycylcycline antibiotic and bacteriostatic protein synthesis inhibitor used in research on susceptible and multidrug-resistant bacteria. Its activity in particular models does not establish activity against every resistant isolate, so findings should be interpreted alongside isolate-specific susceptibility data and the limits of the cited evidence.
-
Machine Learning for Senolytic Discovery
2026-09-23
The reference study demonstrates that cost-effective machine learning trained on published, heterogeneous data can identify senolytic candidates without requiring a large proprietary screening dataset. Experimental validation of ginkgetin, periplocin, and oleandrin shows how computational prioritization can reduce early-stage screening costs while preserving a route to biologically relevant discovery.
-
Faropenem sodium: Applied Assays and Troubleshooting
2026-09-22
Faropenem sodium is a penem antibiotic suited to comparative assays spanning Gram-positive, Gram-negative, and anaerobic organisms. This practical guide connects PBP-driven inhibition with renal transporter biology, offering workflow parameters, controls, and troubleshooting strategies for antimicrobial and antibiotic resistance studies.
-
Cefepime (BMY-28142) in Resistance Workflows
2026-09-22
Cefepime (BMY-28142) supports reproducible antibacterial, central nervous system infection research, and neurotoxicity workflows when concentration, exposure time, and cellular controls are tracked together. This guide translates semi-mechanistic resistance modeling into practical bacterial infection model designs without treating MIC alone as a complete measure of drug response.
-
Estradiol, Autophagy, and Perimenopausal Organ Protection
2026-09-21
This study integrates NHANES analysis, network pharmacology, and a perimenopausal mouse model to examine how declining estradiol relates to cardiovascular, renal, and metabolic vulnerability. Its central contribution is the proposal, supported by receptor and autophagy inhibitor experiments, that estrogen receptor–dependent autophagy helps limit fibrosis across the heart, aorta, and kidneys.
-
Sisomicin for In Vitro Antibacterial Testing
2026-09-21
Sisomicin provides a practical aminoglycoside antibiotic benchmark for susceptibility profiling across clinically important Gram-negative and Gram-positive isolates. This workflow translates historical clinical-isolate data into reproducible microtiter testing, resistance-aware comparisons, and troubleshooting decisions for modern antibacterial research.